Published in Hepatitis Weekly, June 9th, 2008
"Limitations include failure in around 5% of cases, mainly in obese patients. So far, TE has been mostly validated in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.